Kepos Capital’s Sage Therapeutics SAGE Stock Holding History

Kepos Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-8,879	Closed	-$1.25M	–	396
2018 Q3	$1.25M	Buy	+8,879	New	+$1.37M	0.06%	207

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Kepos Capital's SAGE Position: Q4 2018 in Review

Kepos Capital sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 8,879 shares — an estimated $1.25M sold.

Kepos Capital first reported a position in SAGE in Q3 2018 and held it in 1 quarter. The position peaked at $1.25M in Q3 2018. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

Kepos Capital reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
Kepos Capital sold 8,879 Sage Therapeutics shares in Q4 2018, an estimated $1.25M.
Kepos Capital first reported a position in Sage Therapeutics in Q3 2018 and held it in 1 quarter.
Kepos Capital's Sage Therapeutics position peaked at $1.25M in Q3 2018.
248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.